Armata Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Los angeles , may 7, 2024 /prnewswire/ -- armata pharmaceuticals, inc. (nyse american: armp) ("armata" or the "company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended march 31, 2024, and provided a corporate update.  first quarter 2024 and recent developments: entered into a $35.0 million secured credit agreement with innoviva strategic opportunities llc, a wholly-owned subsidiary of innoviva, armata's principal shareholder.

Los angeles , march 21, 2024 /prnewswire/ -- armata pharmaceuticals, inc. (nyse american: armp) ("armata" or the "company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended december 31, 2023, and provided a corporate update.  fourth quarter 2023 and recent developments: continued to advance the phase 2a portion of the company's disarm study of ap-sa02 as a potential treatment for staphylococcus aureus bacteremia with continued ability to dose escalate due to phage purity, as well as its phase 2 tailwind study of ap-pa02 in patients with non-cystic fibrosis bronchiectasis (ncfb).

Proceeds to be used to continue to advance rigorously designed clinical trials of armata's high purity phage-based therapeutic candidates los angeles , march 4, 2024 /prnewswire/ -- armata pharmaceuticals, inc. (nyse american: armp) ("armata" or the "company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with innoviva strategic opportunities llc, a wholly-owned subsidiary of innoviva, inc. (nasdaq: inva) (collectively, "innoviva"), armata's largest shareholder. the gross proceeds to be received by the company at closing are $35 million before deducting transaction-related expenses.

Los angeles , feb. 21, 2024 /prnewswire/ -- armata pharmaceuticals, inc. (nyse american: armp) ("armata" or the "company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that mina pastagia, m.d., chief medical officer, will deliver a presentation at the 6th annual bacteriophage therapy summit, which is being held february 27-29 in boston.

Los angeles , nov. 14, 2023 /prnewswire/ -- armata pharmaceuticals, inc. (nyse american: armp) ("armata" or the "company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended september 30, 2023, and provided a corporate update. third quarter 2023 and recent developments: reported accelerating enrollment in the phase 2a portion of the disarm study of ap-sa02 as a potential treatment for staphylococcus aureus bacteremia, as well as the phase 2 tailwind study of ap-pa02 in non-cystic fibrosis bronchiectasis (ncfb) patients with pseudomonas aeruginosa lung infections.

Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.

Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.30 per share a year ago.

Armata Pharmaceuticals, Inc. (ARMP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

MARINA DEL REY, Calif. , Nov. 28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the company will participate in the H.C.

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0% and 98.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of -50% and 30.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MARINA DEL REY, Calif., Feb. 17, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in two upcoming investor conferences.

Armata Pharmaceuticals, Inc. (ARMP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Armata Pharmaceuticals, Inc. (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.